Online Safety Community

PharmAbcine Announces FDA Orphan Drug Designation Granted to TTAC-0001

PharmAbcine Inc., a clinical-stage biotech company developing novel antibody therapeutics for multiple cancer indications, announced today that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its leading clinical compound TTAC-0001 for “treatment of Glioblastoma Multiforme.”

“We are very pleased with this Orphan Drug Designation from FDA for TTAC-0001 for GBM treatment since we have been preparing for clinical studies of TTAC-0001 plus KEYTRUDA® (pembrolizumab) combo therapy for recurrent GBM in addition to TTAC-0001 mono therapy for recurrent GBM progressed after bevacizumab treatment. It will accelerate the progress of TTAC-0001 to provide clinical benefit in the treatment of GBM,” said Dr. Jin-San Yoo, president and chief executive officer of PharmAbcine, Inc.

The FDA Office of Orphan Products Development grants Orphan Drug Designation to investigational drugs and biologics that are intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S. Orphan drug status is intended to facilitate drug development for rare diseases and may provide several benefits to drug developers, including seven years of market exclusivity upon regulatory product approval, exemptions from certain FDA application fees, and tax credits for qualified clinical trials costs.

gene-therapyhttps://compliance4all14.files.wordpress.com/2018/04/gene-therapy.jpg?w=150&h=85 150w, https://compliance4all14.files.wordpress.com/2018/04/gene-therapy.j... 300w, https://compliance4all14.files.wordpress.com/2018/04/gene-therapy.jpg 600w" sizes="(max-width: 482px) 100vw, 482px" width="420" height="237" />

About TTAC-0001 (=Tanibirumab)

PharmAbcine’s lead candidate TTAC-0001, an investigational therapy, is a highly selective and potent anti-VEGFR2 (KDR/flk-1) mAb in clinical development for rGBM indications. VEGFR2 is over-expressed in most malignant tumors, such as gastric, liver, non-small cell lung cancer (NSCLC), ovarian, brain, colorectal, and breast cancers and this signaling pathway is a key regulator for tumor angiogenesis.

Increased understanding of the role of VEGF/VEGFR2 in the tumor vessel formation, immune suppressive modulation of tumor micro environment (TME) and the function of the antagonist molecule to disorganized tumor vessel normalization, immune supportive modulation, and ultimately tumor vessel disruption, supports the rationale for evaluating TTAC-0001 in GBM, rGBM and Avastin® (bevacizumab) refractory GBM.

About PharmAbcine Inc.

PharmAbcine is a leading clinical stage biologics company that develops fully human therapeutic antibody (mAb) and next generation multispecific antibody therapeutics based on in-house developed novel platform, DIG-Body, PIG-Body and TIG-Body using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.

PharmAbcine’s fully human antibody libraries and innovative selection system are our priceless proprietary assets. PharmAbcine provides antibody generation services by using antibody library and selection systems. PharmAbcine also provides co-development opportunities with novel antibodies.

50d4f095e86498a42d2d2b15279c2c54

Under the collaboration with SAMSUNG MEDICAL CENTER, PharmAbcine has >300 patients derived cancer stem cell libraries and its animal model system for evaluating internal pipeline development.

Enhanced here to continue the remaining post http://snip.ly/i5rch

Views: 28

Comment

You need to be a member of Online Safety Community to add comments!

Join Online Safety Community

Take our poll!

Take our poll!

Latest Activity

Russel Stuart posted a blog post

Bullying at the Workplace Has to be Countered Holistically

Bullying at the workplace is a serious issue that can have major consequences for employees and the organization. HR has to nip it in the bud before it spirals out of control.Very quickly, bullying includes all or any of these:Swearing at other employeesHarassingHumiliatingThreateningAbusingInterfering in another colleague’s work,Intimidating, and the like.Bullying at the workplace, like violence, is a fact of life. At differing levels, it is prevalent almost globally. Having said this, it is…See More
3 hours ago
Training Doyens posted events
5 hours ago
Nakul Pratap posted blog posts
6 hours ago
Mark Nilson posted events
8 hours ago

Forum

Workplace health and safety Signs 4 Replies

You cannot ignore the importance of safety signs at your workplace. There is no scope to underestimate the important to health and…Continue

Tags: Prohibition, Workplace, Warning, Signs, Safety

Started by healthandsafetysigns. Last reply by Jen McDade on Monday.

Jewellery policy - breakaway pins

Hello,Hopefully someone has come up against this, my employers have implemented a jewellery policy; its a bit over the top but they are keen on enforcing it.As is the tendency with anything…Continue

Tags: watches, heavy machinery, industry, Jewellery

Started by Brent Sep 10.

Secure Yourself From The Impending Danger 3 Replies

The most important thing in life is one’s protection against the impending dangers of life. While working or even at home we all feel the need to be safe because if we have good and safe life, only…Continue

Tags: coverings, Protective

Started by Enna Henry. Last reply by Jen McDade Sep 7.

How To Get The Safest Personal Protective Equipment? 2 Replies

Worried about the safety issues? Feeling a little concerned about the safety factors? Running a company and the safety problems are bothering you? Feel relaxed and look for the best safety solutions…Continue

Tags: equipment, protection, personal

Started by Enna Henry. Last reply by Jen McDade Aug 31.

Safety Books 1 Reply

Please view this brochure and let me know if you are ok with the condition before we can share full books of safety…Continue

Started by Binh, M.S, Grad.IOSH, MIIRSM. Last reply by Jen McDade Aug 31.

Badge

Loading…

© 2018   Created by Safety Community.   Powered by

Badges  |  Report an Issue  |  Terms of Service